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Abstract. Head and neck squamous cell carcinomas 
(HNscc) produce low-molecular-mass factors (low-Mr 
factors, Mr --<25,000), which are antigenically related to the 
immunosuppressive r troviral transmembrane envelope 
protein pl5E. These P15E-related tumour factors are 
thought to be responsible for some immunological im- 
pairments found in these patients (particularly the defective 
monocyte chemotaxis). A sequential and functional 
homology has been reported to exist between a bioactive 
fragment of interferon o~ (IFNo0 and the putative im- 
munosuppressive region of retroviral pl5E (CKS-17). In 
this study we investigated (a) a possible functional and 
structural relationship between pl5E and IFNc~, and (b) the 
presence of and the relationship between pl5E-related low- 
Mr factors and IFNo~ in HNscc patients. We report the 
following results. (a) Recombinant human (rhu) IFNc~ was 
able to inhibit monocyte chemotaxis. (b) The anti-pl5E 
antibodies crossreacted with rhulFN~ in a dot-blot tech- 
nique; however, the anti-IFNc~ antibodies did not crossreact 
with disrupted murine leukaemia virus (pl5E source). 
(c) Low-Mr factors (n = 8-11) prepared from the sera of 
HNscc patients, which inhibit the monocyte chemotactic 
responsiveness, could be adsorbed by the anti-pl5E anti- 
bodies as well as by the anti-IFNo~ antibodies. However, the 
abilities of the factors to adsorb to the two categories of 
antibodies (namely, anti-pl5E and anti-IFNcQ did not cor- 
relate. (d) Immunohistochemically we found IFNc~-related 
epitopes, in almost all HNscc specimens studied (17/18), in 
locations distinctive from those of pl5E-related factors. 
The anti-IFNc~ antibodies used in this study mainly reacted 
with basal epithelial cells close to the basal membrane, the 
prickle and granular cells of the squamous cell carcinomas. 
The anti-pl5E antibodies mainly reacted with corneal 
layers, the granular and prickle cells, and did not react with 
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basal epithelial cells. Our findings suggest hat the im- 
munosuppressive factors produced by HNscc cells are 
heterogeneous and pl5E- and/or IFNc~-related. 
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Introduction 
Head and neck squamous cell carcinoma (HNscc) patients 
show several defects ill cell-mediated immunity [1], most 
notably in chemotactic responsiveness of blood monocytes 
[2]. Removal of the HNscc restores this defective chemo- 
tactic responsiveness [3], indicating that the tumor pro- 
duces immunosuppressive factors. Indeed, low-molecular- 
mass factors (low-Mr factors, Mr --<25,000), which inhibit 
monocyte and macrophage r sponses to chemotaxins, have 
been detected in tumor specimens [4, 5] and sera [6-8] of 
HNscc patients. Interestingly, the effect of these factors has 
been shown to be abrogated with monoclonal antibodies 
(mAb) directed against a retroviral immunosuppressive 
protein, pl5E. This was taken as evidence that these low-Mr 
factors were structurally related to pl5E, and possibly in- 
volved in hampering the defense immune response towards 
cancer cells. 
P15E is the transmembrane envelope protein of several 
animal leukaemogenic retroviruses, such as murine leu- 
kaemia virus (MuLV) and feline leukaemia virus (FeLV), 
and is well known for its immunosuppressive actions 
(reviewed in [9, 10]). A synthetic 17-amino-acid peptide 
(CKS-17), homologous to a highly conserved region in 
several retroviral transmembrane envelope proteins [11], 
has similar immunosuppressive actions, amongst which are 
inhibition of monocyte chemotactic responsiveness [12], 
interleukin-l(IL-1)-mediated monocyte tumour killing 
[13], the respiratory burst of human monocytes [14], the 
mitogen- and alloantigen-stimulated proliferation of human 
lymphocytes [15, 16], immunoglobulin synthesis by 
B lymphocytes [17], interferon 7 (IFN7) production [18], 
human natural kil ler (NK) cell activity [19], and in vivo 
delayed-type hypersensitivity (DTH) to sheep red blood 
cells in mice [20]. 
Recently, Ruegg et al. [21] identified a CKS-17-1ike 
conserved region in human interferon c~ (IFNc~), a small 
fragment which, when presented as a synthetic peptide, 
inhibited proliferation of both the Daudi lymphoblastoid 
cell line and anti-CD3-stimulated human T lymphocytes. 
This fragment exhibited a high degree of amino acid se- 
quential identity (70%) to CKS-17. Recombinant human 
(rhu) IFNc~ (subtype 2) has a similar antiproliferative ac- 
tion. Wegemer et al. [22] have found a peptide (P+: ISP) 
comprised of CKS-17 linked to another p l5E-der ived se- 
quence (rich in polar positive residues) from FeLV, which 
like IFNc~ showed antiviral activity on feline- and murine- 
virus-infected cell lines. These authors postulated that some 
of the biological effects of P+ : ISP are mediated through a 
common pathway shared with IFNot. 
Since an immunosuppressive CKS-17-1ike sequence is 
also present in IFNcz, we tried to establish a homologous 
(chemotactic inhibitory) action between p l5E  and IFN(z 
(Mr = 19,000-26,000 [23]). To verify this possible homol- 
ogous action, we investigated the effect of rhuIFNcz on the 
chemotactic responsiveness of healthy donor monocytes 
(measured with the monocyte polarization assay, which 
represents an early event of the chemotactic responsiveness 
[3, 24] ). We also established the reactivity of the ant i -pl5E/  
CKS-17 antibodies against rhuIFN(z using a dot-blot tech- 
nique, and vice versa (anti-IFN(z antibodies to retroviral 
p l5E).  Furthermore, we were interested in whether the 
pl5E-related HNscc low-Mr factors showed IFN(z related- 
ness. We therefore analysed the immunoreactivity of anti- 
IFNcz antibodies on tumour specimens and sera of HNscc 
patients, and compared these data with the immuno- 
reactivity of the ant i -pl5E/CKS-17 antibodies. 
Materials and methods 
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Table 1. Antibodies and their protein concentrations u ed in different 
methods 
Antibodies Final protein concentrations (pg/ml) 
A B C 
.4F5 25 25 25 
19F8 25 25 25 
4F5/19F8 ND 25/25 ND 
ER-IS5 25 25 25 
ER-IS 1 25 ND 25 
Anti-IFNc~ (mAb) 30 30 15 
Anti-IFNc~ (pAb) 10 10 5 
Control IgG2a 25 25 25 
Control IgG2b 25 25 25 
Control IgG1 30 30 15 
Control IgM 25 ND 25 
Control IgGs 10 10 5 
RaM-PO 10 ND 10 
SaR-PO 10 ND 10 
A, Immunohistochemistry; B, adsorption experiments:; C, dot-blot 
technique; ND, not determined; RaM-PO and SaR-PO, peroxidase- 
labelled rabbit anti-(mouse Ig) and swine anti-(rabbit Ig) 
Secondary antibodies used were swine anti-(rabbit Ig) and rabbit anti- 
(mouse Ig) conjugated to horseradish peroxidase (SaR-PO and RaM- 
PO) (Dakopatts, Copenhagen, Denmark). 
ImmunohistochemistlT. Sections of 4 ~tm thickness were cut using a 
cryostat, mounted on glass slides, air-dried and acetone-fixed for 
10 rain. These sections were pre-incubated with tenfold-diluted normal 
sera (Dakopatts, Copenhagen, Denmark) depending on the primary 
antibody step used; normal rabbit serum (using mAb) and normal 
swine serum (using pAb). The sections were subsequently incubated 
for 60 rain with the different specific antibodies mentioned above (and 
controls), washed three times with phosphate-buffered saline (PBS, 
pH 7.4), and incubated for 30 rain with peroxidase-conjugated im- 
munoglobulins. Subsequently the sections were stained[ using chro- 
magen 1,2-diaminobenzidine (Sigma Chemical Corp., st. Louis, 
USA), and weakly counterstained with haematoxylin. All the steps 
described were performed at 21 ~ C, and antibody dilutions were made 
in PBS/I% bovine serum albumin (Sigma Chemical Co., St. Louis, 
USA). 
Antibody protein concentrations were used as shown in Table 1. 
Patients. We studied 18 male and 7 female patients, aged 37-72 years, 
with HNscc of the oral cavity, larynx and oro- and hypopharynx; stages 
T1N2-T4N2. All patients were treated by surgery and/or adiotherapy 
at the department ofear, nose and throat/head and neck surgery of the 
Dijkzigt University Hospital, Rotterdam, the Netherlands. 
After surgery, neoplastic tissues were snap-frozen in liquid nitro- 
gen and stored at -70 ~ C. Serum samples were obtained by venapunc- 
ture and stored at -20 ~ C until use. 
Monoclonal and polyclonal antibodies. Anti-(MuLV)pl5E mAb used 
were 19F8 [25, 26] (IgG2b) and 4F5 [26, 27] (IgG2a). Anti-CKS-17 
mAb, directed against CKS-17-cysteine coupled to keyhole limpet 
haemocyanin (KLH), have been developed atour department (Dr. M. S. 
Lang, manuscript in preparation). Two anti-CKS-17 mAb were used, 
ER-IS5 (IgG2b) and ER-IS1 (IgM; called CK1 in [26]). 
Anti-rhuIFN(z2b mAb (IgG1) and polyclonal antibodies (pAb) 
(IgGs) were a generous gift from Dr. R van der Meyde, TNO Health 
Research, Rijswijk, the Netherlands. 
Control antibodies used were: IgG2a and IgG1 (isotype controls: 
Becton Dickinson), IgG2b (ICN 64-337 (myeloma source), ICN 
Biomedical Inc., Costa Mesa, Calif., USA), IgM (blood group antigen 
A, Dakopatts, Copenhagen, Denmark) and IgGs (rabbit anti-ox red 
blood cells, Seralab Ltd., Crawley Down, GB). 
Isolation of peripheral blood monocytes. Monocytes ]From healthy 
donors were isolated via counterflow elutriation centrifugation [7, 12]. 
These almost pure monocyte fractions were used to test the effects of 
low-Mr factors in sera of HNscc patients and rhuIFNc~2b on the po- 
larization assay (see below). In brief, mononuclear cells were sepa- 
rated from 450 ml whole blood of healthy individuals via Percoll 
centrifugation (20 rain, 1000 g). Thereafter, the mononuclear cells 
were injected into an elutriation centrifugation systetn (Beckman J21 
centrifuge with a JE-6 elutriation rotor). The elutriation medium was 
PBS with 13 mM trisodium citrate and 0.5% human albumin. To se- 
parate the different cell populations, the flow rate wag kept constant at 
20 ml/min, while the rotor speed decreased from 4000 to 0 rpm. The 
fraction collected at 2500 rpm contained 93%-97% non-specific-es- 
terase-positive cells [28]. This fraction was used in further experiments 
after storage in liquid nitrogen as described previously [12]. 
The monocyte polarization assay. The Cianciolo and Snyderman [24] 
assay for monocyte polarization was performed with slight modifica- 
tions [3]. The outcomes of the assay correlate well with the outcomes 
of the conventional Boyden chamber assay to measure chemotaxis to 
formylmethionylleucylphenylalanine (fMetLeuPhe) and casein [3, 24]. 
Aliquots (0.2 ml) of elutriator-purified cell suspension, containing 
0.2x 106 monocytes thawed and washed in RMPI-1640 medium sup- 
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plemented with 10% fetal calf serum (Gibco, Breda, the Netherlands), 
2 mM glutamine and antibiotics, were added to 12x75-mm poly- 
propyleue tubes (Falcon Labware Division of Becton Dickinson Corp., 
Oxford, Calif., USA) containing 0.05 ml medium or fMetLeuPhe (final 
concentration of 10 nM), or with fMetLeuPhe in combination with 
HNscc low-Mr factors, before and after adsorption with the different 
antibodies (see below), or rhuIFNc~2b. The tubes were incubated at 
37 ~ C in a waterbath for 15 rain. The incubation was then stopped by 
addition of 0.25 ml ice-cold 10% formaldehyde in 0.05 M PBS 
(pH 7.4). The cell suspensions were kept at 4 ~ C until counting in a 
haemocytometer using an ordinary light microscope (magnification 
250x). The test was read "blindly" by two persons; 200 cells were 
counted from each tube. A cell was "polarized" if any of the following 
features occurred: (a) elongated or triangular shape; (b) broadened 
lamellipodia; (c) membrane ruffling. 
The percentage of polarized monocytes was calculated as follows: 
total cells polarized (%) 
x 100 
ceils positive for non-specific esterase (%) 
Lymphocytes do not exhibit any polarization activity towards 
fMetLeuPhe [3]. Depending on the donor, 25%-40% of the mono- 
cytes polarized in response to fMetLeuPhe (spontaneous polarization 
4%-9%). 
The effect of low-molecular-mass factors in sera from patients with 
head and neck squamous cell carcinoma and recombinant human 
IFN(x2b on the monocyte polarization assay. Sera were collected as 
mentioned above and diluted 1 : 1 in PBS. These dilutions were sub- 
jected to ultrafiltration through Amicon CF25 Centriflo cones (Amicon 
Corp., Danvers, USA) for 15 rain at 700 g (Mr "cut-off point" 25,000). 
The filtrates, low-Mr factors, were dissolved in PBS and stored at - 
20 ~ C. 
The capability of low-Mr factors or rhuIFNc~2b (Intron A; Schering 
Corp., Kenilworth, N.J., USA) to influence the fMetLeuPhe-induced 
polarization of healthy donor monocytes was determined by incubating 
the monocytes (lxl06/ml) for 15 rain at 37 ~ C, either with fMet- 
LeuPhe alone, or with the tripeptide in combination with low-Mr 
factors (final dilution 1 : 60) or different concentrations of 
rhulFNe~2b (final concentrations 5 pM-500 nM). The percentage 
inhibition was calculated as follows: 
P2 -P0  
inhibition (%) = (1 - - - )  x 100 
P1-  Po 
where P0 = spontaneous polarization (%), P1 = polarization after in- 
cubation with fMetLeuPhe (%) and P2 = polarization after incubation 
with fMetLeuPhe and low-Mr factors or rhuIFN~. 
Low-Mr factors and rhuIFNc~2b were tested in triplicate, the 
addition of either of these to donor monocytes unstimulated by 
fMetLeuPhe did not affect the spontaneous polarization. 
Adsorption experiments. To validate the p 15E-like character of low-Mr 
factors, adsorption experiments were performed by neutralizing the 
factors before testing their effects on the monocyte polarization assay, 
with anti-pl5E antibodies, at 4 ~ C for 16 h and then carrying out 
Amicon ultrafiltration (see above) to remove the antibody-antigen 
complexes formed. The same procedures were performed for in- 
vestigating the expression of the CKS-17 domain with an anti-CKS-17 
antibody (ER-IS5) and expression of IFNc~2b determinants with anti- 
IFNc~2b antibodies. As control antibodies we used irrelevant mAb and 
a pAb. Antibody protein concentrations were used as shown in Table 1. 
Dot-blot technique. Rauscher MuLV (~ 1.0 mg proteirdml), purified as 
described elsewhere [29] from the JLS-V5 cell line, and rhuIFNc~2b 
(~0.1 mg rhuIFNc~2b/ml) were applied as dots directly onto ni- 
trocellulose strips (Bio-Rad Lab., Richmond, Calif., USA) in 5-gl 
volumes, and dried at 70 ~ C for 1 h. The remaining protein-binding 
sites were blocked with PBS/0.05% gelatin (Gibco Europe Ltd., 
Paisley, Scotland) for at least i h. The nitrocellulose strips were then 
incubated overnight with anti-pl5E, anti-CKS-17 and anti-IFNa2b 
antibodies. Bound antibodies were detected with specific conjugates, 
SaR-PO and RaM-PO, during a 2-h incubation step. All incubations 
were performed at 21 ~ C with slow agitation, and between these steps 
the strips were washed three times with PBS/0.05% Tween 20 (Merck, 
Mtinchen, Germany). The strips were developed by 0.01% H~O2 and 
1.7 mM 4-chloro-l-naphthol (J. T. Barker B. V., Deventer, The 
Netherlands) in 50 mM TRIS/HC1 buffer (pH 7.2), 7% poly- 
ethyleneglycol 6000 (Sigma Chemical Co., St. Louis, USA), for 5 -  
10 rain. Antibody protein concentrations were used as shown in 
Table 1. 
Resu l ts  
Effect of  recombinant human 1FNo~2b on the monocyte 
polarization 
Since IFNc~ has sequential similarit ies to retroviral p15E 
(see Introduction), we were interested in whether it was 
capable of inhibit ing the polarization of  healthy monocytes.  
As shown in Fig. 1, rhuIFNc~2b strongly inhibited the 
polar izat ion of  healthy monocytes  in a dose-dependent 
manner, with a concentrat ion of ha l f -max imum inhibit ion 
(ICs0) of  about 100 nM (max imum inhibit ion 100 %; P2 = P0, 
see Materials and methods). This inhibitory activity of 
rhuIFNc~2b could not be ascribed to pept ide-mediated 
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Fig. 1. The percentage inhibition of various concen- 
trations of recombinant human interferon c~2b 






Fig. 2. Immunoreactivity (dot-blot echnique) of rhuIFNc~2b (A) and 
MuLV-pl5E (B) using the following antibodies: a representative Ig 
control (1), anti-p15E antibodies 4F5 (2), and 19F8 (3), anti-CKS-17 
antibodies ER-IS1 (4) and ER-IS5 (5), and anti-IFNo~ mAb (6) and 
pAb (7) 
(500 nM) and incubation periods of up to 1 h, none of the 
monocytes howed altered morphology and an increased 
trypan blue uptake (data not shown). 
Dot-blot technique 
To study a possible structural homology between retroviral 
p l5E  and human IFNcz, we also investigated whether the 
specific antibodies reacted with immobil ized rhuIFNo~2b 
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and/or detergent-disrupted MuLV as a source of p l5E,  in 
comparison wih isotype and matched control antibodies. 
Figure 2 shows that anti- IFN~ antibodies reacted with 
rhuIFN(~2b, but did not show any reactivity with (dot) 
blotted disrupted MuLV, indicating that these antibodies 
showed specificity for rhuIFN~. The ant i -pl5E antibodies 
(19F8 and 4F5) reacted with both rhuIFNc~2b and disrupted 
MuLV, indicating that these antibodies were not only spe- 
cific for retroviral p l5E  but also crossreacted at least to a 
certain extent with IFNo~. The anti-CKS-17 antibodies (ER- 
IS5 and ER-IS 1) showed differential patterns of reactivity. 
Whereas ER-IS 1 clearly reacted with both rhulFNc~2b and 
MuLV, ER-IS5 only very weakly reacted to disrupted 
MuLV. 
Interestingly, the ant i -pl5E and anti-IFNc~-specific an- 
tibodies were also able to adsorb the rhuIFN~ (500 nM) 
inhibitory effect on the monocyte polarization (data not 
shown), confirming the reactivity of all these antibodies 
with rhulFNcz shown in the dot-blot experiments. 
Reactivity of anti-pl 5E, anti-CKS-I7 and anti-IFNo~ 
antibodies with immunosuppressive low-molecular-mass 
factors from the sera of patients with head and neck 
squamous cell carcinoma 
Low-Mr factors prepared from the sera of patients with 
HNscc inhibit the polarization of normal monocytes [6 -  8]. 
Table 2 shows the results of adsorption experiments on the 
low-Mr factors prepared for serum preparations (n = 8 -11)  
with the antibodies used in this study (see Table 1). The 
monocyte chemotaxis-inhibitory effect of all low-Mr fac- 
tors tested could be adsorbed - as has been (eported before 
- by the ant i -pl5E antibodies 19F8 (3 out of 3 HNscc sera 
tested) and 4F5 (3 out of 3) just as well as by a mixture of 
these two mAb (8 out of 8). 
Table 2. The percentages inhibition by low-Mr factors prepared from sera of patients with head and neck squamous cell carcinoma on the 
fMetLeuPhe-induced monocyte polarization, before and after adsorption with antibodies directed against retroviral MuLV-pl5E, its putative 
immunosuppressive (synthetic) CKS-17-region and rhuIFNc~; the difference in inhibition of the polarization after adsorption between specific 
antibodies and their matching isotype controls was evaluated using the Wilcoxon's rank-sum test 
Low-Mr Inhibition of the monocyte polarization (%) after adsorption with 
factors 
None 4F5/ 4F5 19F8 ER-IS5 Isotype a Anti -b Isotype c Anti-d Isotype  
19F8 control IFNc~ control IFNc~ control 
A 48 13 24 19 23 55 12 48 25 36 
B 40 16 27 31 15 42 15 40 4 41 
C 41 25 22 34 16 47 15 41 19 41 
D 67 32 ND ND 42 48 11 48 49 58 
E 47 33 ND ND 28 44 30 50 28 66 
F 61 20 ND ND 51 60 42 57 49 48 
G 54 38 ND ND 29 64 62 39 29 59 
H 51 30 ND ND 48 64 26 54 27 54 
I 45 ND ND ND ND ND 34 ND ND ND 
J 43 ND ND ND ND ND 20 ND ND ND 
K 39 ND ND ND ND ND 19 ND ND ND 
Mean 49 26 24 28 32 53 26 47 29 50 
SD 9 9 14 9 15 7 15 11 
P <0.001 <0.02 <0.01 <0,02 
ND, not determined; a IgG2a/b; b mAb; c IgG1; d pAb; e IgGs 
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Fig. 3 A-D. Immunohistochemical staining of head and neck squamous cell carcinoma specimens u ing the following antibodies: a representative 
Ig control (A), anti-pl5E antibody 4F5 (B), anti-IFNa pAb (C) and anti-CKS-17 antibody ER-IS1 (D) (magnification 150x) 
Interestingly, anti-IFN~2b mAb and pAb were also 
capable of adsorbing the inhibitory effect of the low-Mr 
factors. Since the anti-IFNo~ antibodies are specific to IFNo~ 
(dot-blot technique) and do not react with MuLV-pl5E, the 
data of Table 2 must be taken as evidence that the majority 
of the low-Mr factors do contain IFNc~-like molecules as 
immunosuppressive factors. 
However, we could not find a correlation between the 
adsorption capabilities of the anti-IFNo~ antibodies and the 
anti-p15E antibodies, and it is thus possible that the low-Mr 
factors contain both pl5E- and IFNc,-related factors. It is 
also possible that different affinities of the antibodies, to- 
gether with heterogeneity of the low-Mr factors, explain the 
non-correlation. 
The relatively weak (as shown in the dot-blot experi- 
ment) anti-CKS-17 mAb ER-IS5 adsorbed the inhibitory 
activity of these inhibitory low-Mr factors to a certain ex- 
tent (6 out of 8), indicating that these low-Mr factors ex- 
press the CKS-17-1ike domain, as has been demonstrated 
previously [26]. 
Immunohistochemistry of head and neck squamous cell 
carcinoma specimens with anti-pl5E, anti-CKS-17 and 
anti-IFNo~ antibodies 
In accordance with our previous reports [5, 26] all (n = 18) 
HNscc tissue specimens tudied showed a positive re- 
activity with both anti-retroviral pl5E antibodies used, 
namely 19F8 and 4F5. These antibodies recognize different 
epitopes on retroviral pl5E [27]; 19F8 is directed to an 
epitope in the CKS-17 domain [26]. Antibody 4F5 gave the 
best results in the immunohistochemistry (Fig. 3b), with 
practically no background staining. The positivity with the 
antibodies was mainly detected in corneal ayers of well- 
differentiated tumours, and in the granular epithelial cells 
and prickle cells, staining the whole cytoplasm. Basal cells 
close to the basal membrane were often negative. 
Anti-IFNo~ mAb and pAb also gave positive staining 
results with almost all (17/18) HNscc tumour specimens. 
However, the location of the reactivity was different from 
that of the anti-pl5E antibodies, particularly in the case of 
the anti-IFNc~ pAb (Fig. 3 c). This latter antibody clearly 
reacted with malignant cells in the basal epithelial cell 
layers close to he basal membrane, as well as with the 
prickle cell layers. Though this antibody was often reactive 
to some extent o granular cells and the corneal layers, this 
reactivity was not as strong as the reactivity with the anti- 
pl5E antibodies. 
The anti-CKS-17 antibodies, ER-IS5 and ER-IS1, gave 
staining results combining the results of the anti-pl5E and 
anti-IFNo~ antibodies: in fact, all layers of the tumours were 
clearly reactive with these antibodies. It must be noted that 
ER-IS1 gave for stronger immunostaining results (Fig. 3 d) 
than did ER-IS5, which appeared to be an antibody with 
low affinity (see dot-blot and adsorption experiments). 
183 
Discussion 
In the present study we have shown that rhuIFN~b shares 
functional (monocyte polarization experiments) and struc- 
tural (dot-blot technique) homology to retroviral pl5E. 
Furthermore, our data show that low-Mr factors, prepared 
from the sera of HNscc patients, do not only contain factors 
related to retroviral pl5E (as was shown extensively in 
earlier studies), but also factors that show antigenic simi- 
larity to IFNa. These factors appear to be separate, since 
there were discrepancies found in (a) the low-Mr factor 
adsorption data and (b) the immunohistochemistry staining 
results with anti-p 15E and anti-IFNc~ antibodies. 
IFNc~ (3//1- = 19,000-26,000 [23]), well known for its 
antiviral actions [30], has been reported to have a wide 
range of immunosuppressive activities. In vivo, IFNo~ has 
been shown to decrease DTH responses in mice sensitized 
with sheep red blood cells [31]. In addition, the generation 
of antibody-producing cells was inhibited by IFNc~ when it 
was administered prior to sensitization with sheep red 
blood cells [32]. In vitro, IFNc~ is antiproliferatively active 
[30] and suppresses T-helper lymphocytes to stimulate an- 
tibody production by B lymphocytes [33]. Furthermore, 
functional suppression of monocytes/macrophages has been 
described: inhibition of IFNT-induced-I-ILA-DR expression 
[34], -tumoricidal activity [35] and -respiratory burst [36] 
on macrophages, and blocking of IL-l-induced pros- 
taglandin release from monocytes [37] (IL-1 inhibitor). 
Moreover, IFNo~ suppresses the in vitro maturation from 
human monocytes to macrophages (down-regulation of 
phagocytosis, complement receptors and lysosomal en- 
zymes [381). 
In this report we complement these functional studies on 
1FNc~ by showing that rhuIFNa2b also inhibits fMet- 
LeuPhe-induced monocyte polarization. Furthermore, using 
a modified Boyden chamber assay it was found that the 
classical chemotaxis is suppressed by rhuIFN(z2b (un- 
published observation). Interestingly, the inhibitory activ- 
ities on monocyte polarization of rhuIFNc~2b were ad- 
sorbed by the anti-retroviral pl5E antibodies. One of the 
latter antibodies, 19F8, recognizes an epitope within the 
immunosuppressive CKS-17 domain [26]. It is of particular 
interest that the sequence recognized by this mAb, 
LQNRRGLD (one-letter amino-acid code), is the sequence 
that is most similar to a homologous sequence within IFNc~ 
[21, 22]. This sequence has been postulated to be the 
minimally required sequence for immunosuppressive ac- 
tivity [16]. Previous studies [21, 22] have shown that the 
putative immunosuppressive site of retroviral pl5E, CKS- 
17, also has IFNc~-like antiviral and antiproliferative ac- 
tivities. Moreover, our adsorption results suggest hat a 
sequence similar to LQNRRGLD is clearly expressed in the 
immunosuppressive serum factors from HNscc patients. 
With regard to our finding of the IFNo~-relatedness of at 
least some of the (HNscc sera) low-Mr factors, Sato et al. 
[39] have earlier found IFN activity in the sera of HNscc 
patients. This activity was abrogated with acid treatment. In 
other patient groups characterized by clear immune dis- 
orders, such as patients with systemic lupus erythematosus 
[40] or AIDS [41], atypical acid-labile IFNc~ has been de- 
monstrated. It must be noted, however, that this acid lability 
was due to an acid-labile molecule, associated with, but 
distinct from "normal" (acid-stable) IFNc~ [42, 43]. In hu- 
mans, it has been shown that there are at least 15 highly 
related IFNo~ subtypes [23], each with characteristic 
chemical and biological activities. For instance, while 
IFNc~ is generally known to be an activator of NK cell 
activity [30], the subtype IFNc~J lacks this ability and may 
even block the NK-boosting activity of other IFNo~ sub- 
types [44] (e. g. IFNc~A). Hence, IFN(x subtypes may exist 
that antagonize the immunostimulating activities of other 
subtypes and may even be primarily immunosuppressive. 
It is tempting to suggest hat the immunosuppressive 
factors found in HNscc are in fact related to these subtypes 
of IFNc~, and even that pl5E-related factors may be in- 
cluded in the IFNc~ family. 
In conclusion, antigenic similarities observed in this 
study between pl5E, its synthetic CKS-17 domain and 
human IFNo~, and their known immunosuppressive action 
on different immunocompetent "target" cells, suggest a 
relationship between inhibitory HNscc p 15E-related factors 
and human IFNc~. It is likely that HNscc produce a set of 
heterogeneous factors that are IFN(~- and/or pl5E-related 
and exhibit inhibitory effects on monocyte chemotaxis. 
Isolation, purification and sequencing of HNscc im- 
munosuppressive factors is of the utmost importance to 
determine whether these ill-defined factors are indeed re- 
lated to the IFNc~ family, form a separate variety of pro- 
ducts of (endogenous) retroviruses or represent cross- 
reacting activities. 
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